Case number 1:21-cv-01105
Novartis Pharmaceuticals Corporation v. Lupin Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 8, 2023 | 94 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Consent Judgment)(mdb) (Entered: 12/08/2023) (0) |
| Dec 5, 2023 | 93 | CONSENT JUDGMENT AND ORDER OF INJUNCTION. Signed by Judge Maryellen Noreika on 12/5/2023. ***CIVIL CASE TERMINATED*** (dlw) (Entered: 12/05/2023) (4) |
| Dec 4, 2023 | 92 | PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendant Lupin Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/5/2023 (dlw). (Entered: 12/04/2023) (4) |
| Dec 1, 2023 | 88 | REDACTED VERSION of (82 in 1:21-cv-01105-MN) Opening Brief in Support, (105 in 1:21-cv-01107-MN) Opening Brief in Support, (88 in 1:21-cv-01106-MN) Opening Brief in Support, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (16) |
| Dec 1, 2023 | 89 | REDACTED VERSION of (83 in 1:21-cv-01105-MN, 89 in 1:21-cv-01106-MN, 106 in 1:21-cv-01107-MN) Declaration, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 90 | REDACTED VERSION of (107 in 1:21-cv-01107-MN) Joint Claim Construction Brief, (90 in 1:21-cv-01106-MN) Joint Claim Construction Brief, (84 in 1:21-cv-01105-MN) Joint Claim Construction Brief by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 91 | REDACTED VERSION of (108 in 1:21-cv-01107-MN, 85 in 1:21-cv-01105-MN, 91 in 1:21-cv-01106-MN) Appendix, by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Pt.2 of 2)(Joyce, Alexandra) (Entered: 12/01/2023) (0) |
| Nov 27, 2023 | 87 | STIPULATION TO EXTEND TIME regarding the deadline to submit redacted public versions of the Joint Claim Construction Brief (D.I. 84 in C.A. No. 21-1105, D.I. 90 in C.A. No. 21-1106, and D.I. 107 in C.A. No. 21-1107) and Joint Appendix (D.I. 85 in C.A. No. 21-1105, D.I. 91 in C.A. No. 21-1106, and D.I. 108 in C.A. No. 21-1107) to December 1, 2023 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/27/2023) (4) |
| Nov 22, 2023 | 86 | STIPULATION TO EXTEND TIME for Briefing Schedule regarding Plaintiffs' Daubert Motion to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh to See Stip for Details - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/22/2023) (4) |
| Nov 17, 2023 | 84 | [SEALED] JOINT CLAIM CONSTRUCTION BRIEF filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 85 | [SEALED] Joint APPENDIX re (107 in 1:21-cv-01107-MN) Joint Claim Construction Brief, (90 in 1:21-cv-01106-MN) Joint Claim Construction Brief, (84 in 1:21-cv-01105-MN) Joint Claim Construction Brief by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1-12, # 2 Exhibit 13-24, # 3 Exhibit 25-36)(Joyce, Alexandra) (Entered: 11/17/2023) (0) |
| Nov 16, 2023 | 80 | ORAL ORDER - IT IS HEREBY ORDERED that the parties shall engage in in-person mediation in good faith. The parties are to jointly hire an agreed-upon mediator. The timing of mediation efforts is left to the discretion of the parties, but the mediation must be conducted in advance of the pretrial conference. No later than one week before the pretrial conference, the parties shall submit a joint statement that identifies the mediator, the lead counsel for each party at the mediation and the length of the mediation, as well as a certification by the lead counsel that they have engaged in the mediation efforts in good faith. The joint statement should not disclose the substance of any offers, counteroffers or other negotiations. If the parties anticipate any further mediation efforts will be conducted after the deadline to submit the joint statement, the parties shall indicate that in their submission and state when those efforts are expected to occur. ORDERED by Judge Maryellen Noreika on 11/16/2023. (dlw) (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 81 | MOTION to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order, # 2 Certification of Counsel Pursuant to Local Rule 7.1.1.)(Joyce, Alexandra) Modified on 11/16/2023 (mdb). (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 82 | [SEALED] OPENING BRIEF in Support re 81 MOTION to Exclude Opinion Testimony from Defendants' Putative Expert Dr. Mohamad Khasawneh filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 11/30/2023. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) Modified on 11/16/2023 (mdb). (Entered: 11/16/2023) (0) |
| Nov 16, 2023 | 83 | [SEALED] DECLARATION of Robert W. Trenchard re (82 in 1:21-cv-01105-MN) Opening Brief in Support, (105 in 1:21-cv-01107-MN) Opening Brief in Support, (88 in 1:21-cv-01106-MN) Opening Brief in Support by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1-6, # 2 Certificate of Service)(Joyce, Alexandra) Modified on 11/20/2023 (dlw). (Entered: 11/16/2023) (0) |
| Nov 15, 2023 | 78 | NOTICE OF SERVICE of Defendants' First Set of Requests for Admission (Nos. 1-33) filed by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) (Entered: 11/15/2023) (2) |
| Nov 15, 2023 | 79 | NOTICE OF SERVICE of Joint Defendants' Highly Confidential Sur-Reply Claim Construction Brief with Exhibits filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 11/15/2023) (2) |
| Nov 9, 2023 | 77 | NOTICE OF SERVICE of Plaintiffs' Reply Claim Construction Brief filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/09/2023) (5) |
| Nov 3, 2023 | 76 | NOTICE OF SERVICE of Joint Defendants' Highly Confidential Answering Claim Construction Brief with Exhibits filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 11/03/2023) (2) |
| Oct 27, 2023 | 75 | NOTICE OF SERVICE of Plaintiffs' Opening Claim Construction Brief and Exhibits filed by Novartis Pharmaceuticals Corporation, Dana-Farber Cancer Institute, Inc..(Joyce, Alexandra) (Entered: 10/27/2023) (5) |
| Oct 17, 2023 | 74 | ORAL ORDER re (94 in 1:21-cv-01107-MN, 79 in 1:21-cv-01106-MN, 73 in 1:21-cv-01105-MN) Letter - Having reviewed the parties' October 16, 2023 letter, IT IS HEREBY ORDERED that the parties may file claim construction briefing. The briefing shall follow the Court's typical briefing format (i.e., not the simultaneous briefing proposed) and the joint brief (of no more than 40 pages total (i.e., 20 pages for each side)) shall be filed no later than November 17, 2023. The Court will not set a hearing at this time. The parties should address both sides' proposed constructions with respect to positions of infringement, noninfringement, validity and invalidity in their expert reports and the pretrial order and should be prepared to do so at trial if required. ORDERED by Judge Maryellen Noreika on 10/17/2023. (dlw) (Entered: 10/17/2023) (0) |
| Oct 16, 2023 | 73 | Joint Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding proposal for resolving claim construction disputes that arose during expert discovery. (Silver, Daniel) (Entered: 10/16/2023) (2) |
| Oct 2, 2023 | 71 | NOTICE OF SERVICE of (1) Sur-Reply Expert Report of Donald Small, M.D., Ph.D. on the Validity of U.S. Patent No. 7,973,031, (2) Sur-Reply Expert Report of William J. Jusko, Ph.D., and (3) Reply Expert Report of Christopher A. Vellturo, Ph.D. filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/02/2023) (5) |
| Oct 2, 2023 | 72 | NOTICE OF SERVICE of the Sur-Reply Expert Report of Mohamad K. Khasawneh, M.D., on Non-Infringement of U.S. Patent No. 8,575,146 (on behalf of the Lotus, Lupin, and Teva defendants) filed by Lupin Inc..(Lennon, James) (Entered: 10/02/2023) (2) |
| Sep 27, 2023 | 70 | NOTICE OF SERVICE of (1) Reply Expert Report of David P. Rotella, Ph.D., on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146; (2) Reply Expert Report of Mohamad K. Khasawneh on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146; (3) Reply Expert Report of S. Craig Dyar, Ph.D., R.PH; (4) Reply Expert Report of Frederick H. Hausheer, M.D., F.A.C.P.; and (5) Reply Expert Report of Ivan T. Hofmann filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Taylor, Daniel) (Entered: 09/27/2023) (2) |
| Sep 25, 2023 | 69 | NOTICE OF SERVICE of Reply Report of Mark J. Levis, M.D., Ph.D. Regarding Infringement of U.S. Patent No. 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/25/2023) (4) |
| Aug 21, 2023 | 67 | NOTICE OF SERVICE of (1) First Expert Report of Donald Small, M.D., Ph.D. on the Validity of U.S. Patent No. 7,973,031, (2) Expert Report of Mark J. Levis, M.D., Ph.D. on the Validity of U.S. Patent No. 8,575,146, (3) First Expert Report of William J. Jusko, Ph.D., and (4) Expert Report of Christopher A. Vellturo, Ph.D. filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/21/2023) (5) |
| Aug 21, 2023 | 68 | NOTICE OF SERVICE of Rebuttal Expert Report of Mohamad K. Khasawneh, M.D., Regarding Non-Infringement of U.S. Patent No. 8,575,145 (on behalf of the Lotus, Lupin, and Teva defendants) filed by Lupin Inc..(Lennon, James) (Entered: 08/21/2023) (2) |
| Jul 25, 2023 | 66 | STIPULATION TO EXTEND TIME See Stip for Details to - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 07/25/2023) (4) |
| Jun 5, 2023 | 64 | NOTICE OF SERVICE of (1) First Expert Report of Dr. Stephen R. Byrn, and (2) First Expert Report of Dr. Mark J. Levis filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/05/2023) (5) |
| Jun 5, 2023 | 65 | NOTICE OF SERVICE of 1. Opening Expert Report of David P. Rotella, Ph.D., on the Invalidity of U.S. Patent Nos. 7,973,031 and 8,575,146 2. Opening Expert Report of Mohamad K. Khasawneh, M.D., regarding the Invalidity of U.S. Patent Nos. 7, 973,031 and 8,575,146 3. Opening Expert Report of S. Craig Dyar, Ph.D., R.PH 4. Expert Report of Frederick H. Hausheer, M.D. FACP filed by Teva Pharmaceuticals Development, Inc..(Keller, Karen) (Entered: 06/05/2023) (2) |
| May 9, 2023 | 63 | SO ORDERED re (83 in 1:21-cv-01107-MN, 72 in 1:21-cv-01106-MN, 62 in 1:21-cv-01105-MN) Stipulation and Order Regarding Expert Discovery (Set/Reset Scheduling Order Deadlines - Opening Expert Reports due by 6/2/2023. Rebuttal Expert Reports due by 8/4/2023. Reply Expert Reports due by 9/8/2023. Sur-Reply Expert Reports due by 9/22/2023). Signed by Judge Maryellen Noreika on 5/9/2023. (dlw) (Entered: 05/09/2023) (3) |
| May 8, 2023 | 62 | STIPULATION and [Proposed] Order Regarding Expert Discovery by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/08/2023) (3) |
| Mar 10, 2023 | 61 | NOTICE OF SERVICE of Lupins Response to Plaintiffs Notice of Deposition to Lupin Inc. filed by Lupin Inc..(Lennon, James) (Entered: 03/10/2023) (2) |
| Feb 6, 2023 | 60 | STIPULATION TO EXTEND TIME for all fact discovery to be completed to April 19, 2023 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/06/2023) (4) |
| Jan 19, 2023 | 59 | NOTICE to Take Deposition of Lupin Inc. on January 30, 2023 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/19/2023) (7) |
| Jan 9, 2023 | 56 | NOTICE to Take Deposition of Ms. Kalpana Vanam on February 6, 2023 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 9, 2023 | 57 | NOTICE to Take Deposition of Katy Rudnick on February 8, 2023 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 9, 2023 | 58 | NOTICE to Take Deposition of Mr. Jason Gensburger on January 26, 2023 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/09/2023) (2) |
| Jan 5, 2023 | 55 | NOTICE OF SERVICE of 1. Defendants' Notice of Deposition to James Griffin 2. Defendants' Notice of Deposition to Paul Manley 3. Defendants' Notice of Deposition to Richard Stone 4. Defendants' Notice of Deposition to Ellen Weisberg 5. Defendants' Notice of Deposition to Renaud Capdeville filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 01/05/2023) (3) |
| Dec 20, 2022 | 54 | NOTICE OF SERVICE of Lupin's Responses to Plaintiff's Final Infringement Contentions filed by Lupin Inc..(Lennon, James) (Entered: 12/20/2022) (2) |
| Dec 19, 2022 | 53 | NOTICE OF SERVICE of Plaintiffs' Responses to Defendants' Final Invalidity Contentions Regarding U.S. Patent Nos. 7,973,031 and 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/19/2022) (5) |
| Dec 12, 2022 | 52 | NOTICE OF SERVICE of Defendants' Notice of Depositions of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 12/12/2022) (2) |
| Oct 26, 2022 | 51 | NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/26/2022) (5) |
| Oct 25, 2022 | 50 | NOTICE OF SERVICE of Defendants' Final Invalidity Contentions filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) (Entered: 10/25/2022) (2) |
| Sep 21, 2022 | 48 | STIPULATION TO EXTEND TIME to file Final Contentions and to Extend Fact Discovery Deadline to various dates - filed by Accord Healthcare Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Lotus Pharmaceutical Co., Ltd., Teva Pharmaceuticals Development, Inc., Lupin Inc.. (Hoeschen, Nathan) (Entered: 09/21/2022) (4) |
| Sep 21, 2022 | 49 | SO ORDERED re (48 in 1:21-cv-01105-MN, 26 in 1:22-cv-00744-MN, 53 in 1:21-cv-01106-MN, 65 in 1:21-cv-01107-MN) STIPULATION TO EXTEND TIME to file Final Contentions and to Extend Fact Discovery Deadline to various dates (Set/Reset Scheduling Order Deadlines: Fact Discovery completed by 2/10/2023. Claim Construction Scheduling Order Deadlines TERMINATED). Signed by Judge Maryellen Noreika on 9/21/2022. (dlw) (Entered: 09/21/2022) (4) |
| Aug 22, 2022 | 47 | SO ORDERED re (46 in 1:21-cv-01105-MN, 51 in 1:21-cv-01106-MN, 20 in 1:22-cv-00744-MN, 63 in 1:21-cv-01107-MN) Stipulation and Order Regarding Case Coordination. Signed by Judge Maryellen Noreika on 8/22/2022. (dlw) (Entered: 08/22/2022) (6) |
| Aug 19, 2022 | 46 | STIPULATION and [Proposed] Order Regarding Case Coordination by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/19/2022) (6) |
| Aug 8, 2022 | 45 | NOTICE OF SERVICE of Plaintiffs' Identification on Proposed Claim Terms and Constructions filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/08/2022) (5) |
| Aug 3, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (44 in 1:21-cv-01105-MN, 61 in 1:21-cv-01107-MN, 49 in 1:21-cv-01106-MN) Joint STIPULATION TO EXTEND TIME to substantially complete document production to August 23, 2022. ORDERED by Judge Maryellen Noreika on 8/3/2022. (dlw) |
| Aug 3, 2022 | 44 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME to substantially complete document production to August 23, 2022 - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Ormerod, Eve) |
| Jul 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re (48 in 1:21-cv-01106-MN, 60 in 1:21-cv-01107-MN, 43 in 1:21-cv-01105-MN) Joint STIPULATION TO EXTEND TIME 1) for the parties to exchange a list of claim term(s)/phrase(s) needing construction and proposed constructions and 2) to exchange proposed constructions for terms proposed by another party to August 5, 2022 and August 19, 2022, respectively. ORDERED by Judge Maryellen Noreika on 7/29/2022. (dlw) |
| Jul 29, 2022 | 43 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME 1) for the parties to exchange a list of claim term(s)/phrase(s) needing construction and proposed constructions and 2) to exchange proposed constructions for terms proposed by another party to August 5, 2022 and August 19, 2022 respectively - filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Jul 27, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) |
| Jul 15, 2022 | 42 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Plaintiffs' Responses to Defendants Invalidity Contentions Regarding U.S. Patent Nos. 7,973,031 and 8,575,146 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 7, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [41] Stipulation to Extend Time for Plaintiffs to serve responses to Defendants' invalidity contentions (now due 7/15/2022). ORDERED by Judge Maryellen Noreika on 7/7/2022. (dlw) |
| Jul 7, 2022 | 41 | Stipulation (3) Docket Text: STIPULATION and Proposed Order to Extend Time for Plaintiffs to Serve Responses to Defendants' Invalidity Contentions to July 15, 2022 by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2022 (dlw). |
| Jun 7, 2022 | 40 | Scheduling Order (14) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 12/9/2022. Amended Pleadings due by 12/9/2022. Fact Discovery completed by 12/9/2022. Opening Expert Reports due by 5/19/2023. Rebuttal Expert Reports due by 7/21/2023. Reply Expert Reports due by 8/25/2023. Expert Discovery due by 10/27/2023. Daubert Motions due by 11/10/2023. Claim Construction Opening Brief served by 12/16/2022. Claim Construction Answering Brief served by 1/20/2023. Claim Construction Reply Brief served by 2/10/2023. Claim Construction Surreply Brief served by 2/22/2023. Joint Claim Construction Brief filed by 3/3/2023. A Markman Hearing is set for 3/24/2023 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 1/19/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 1/29/2024 at 08:30 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 6/7/2022. (dlw) |
| May 31, 2022 | 39 | Proposed Order (15) Docket Text: PROPOSED ORDER // Scheduling Order by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/2/2022 (dlw). |
| May 18, 2022 | 37 | ANDA Form (2) Docket Text: Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 14, 2021. Date of Expiration of Patent: December 2, 2030. Statutory Stay Deadline: October 28, 2024. (Silver, Daniel) Modified on 5/18/2022 (dlw). |
| May 18, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER - Having reviewed the Amended Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application (ANDA) forms wherein the stay deadline has been updated to reflect the regulatory stay deadline (10/28/2024), IT IS HEREBY ORDERED that the bench trial in these matters will be held on 1/29/2024. The parties shall submit the revised proposed scheduling order (see the Court's 4/18/2022 Oral Order) on or before 6/1/2022. ORDERED by Judge Maryellen Noreika on 5/18/2022. (dlw) |
| May 9, 2022 | 36 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Lupin's Responses to Plaintiff's Preliminary Infringement Contentions filed by Lupin Inc..(Lennon, James) |
| Apr 29, 2022 | 35 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Lupin's Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants (Nos. 1-6); and (2) Lupin's Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-29) filed by Lupin Inc..(Lennon, James) |
| Apr 18, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER re (28 in 1:21-cv-01107-MN, 18 in 1:21-cv-01106-MN, 17 in 1:21-cv-01105-MN) Scheduling Order - IT IS HEREBY ORDERED that the parties shall conform the existing Scheduling Order in these cases to this Court's form. The bench trial will be held the week of 5/15/2023. The parties shall also provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms). If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 4/18/2022. (dlw) |
| Apr 18, 2022 | 34 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiff Novartis Pharmaceuticals Corporation Responses to Defendants' First Set of Requests for Production (Nos. 1-73); (2) Plaintiff Dana-Farber Cancer Institute, Inc.'s Responses to Defendants' First Set of Requests for Production (Nos. 1-73); and (3) Plaintiffs' First Amended Paragraph 3 Disclosures filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 8, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Robert W. Trenchard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Apr 6, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Emil N. Nachman for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 6, 2022 | 32 | Letter (2) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Status Report. (Silver, Daniel) |
| Apr 5, 2022 | 31 | Stipulation (3) Docket Text: Joint STIPULATION to Extend Various dates re (28 in 1:21-cv-01107-LPS) Scheduling Order,, by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Mar 31, 2022 | 30 | Stipulation to EXTEND Time (3) Docket Text: Joint STIPULATION TO EXTEND TIME to file a Joint Status Report to April 6, 2022 - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Ormerod, Eve) |
| Mar 30, 2022 | 29 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Set of Common Interrogatories to All Defendants (Nos. 1-6) & (2) Plaintiffs' First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-29) filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (27 in 1:21-cv-01106-LPS, 25 in 1:21-cv-01105-LPS, 37 in 1:21-cv-01107-LPS) PROTECTIVE ORDER; (38 in 1:21-cv-01107-LPS, 26 in 1:21-cv-01105-LPS, 28 in 1:21-cv-01106-LPS) ORDER for Discovery, Including Discovery of Electronically Stored Information ("ESI"). Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (27 in 1:21-cv-01105-LPS, 39 in 1:21-cv-01107-LPS, 29 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Emil N. Nachman filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 24, 2022 | 27 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Emil N. Nachman - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Emil N. Nachman)(Joyce, Alexandra) |
| Mar 24, 2022 | 27 | Certification for Emil N. Nachman (1) |
| Mar 18, 2022 | 25 | Proposed Order (27) Docket Text: PROPOSED ORDER Protective Order by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 18, 2022 | 26 | Proposed Order (11) Docket Text: PROPOSED ORDER for Discovery, Including Discovery of Electronically Stored Information ("ESI") by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Mar 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (25 in 1:21-cv-01106-LPS, 23 in 1:21-cv-01105-LPS, 36 in 1:21-cv-01107-LPS) STIPULATION TO EXTEND TIME (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 18, 2022 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/11/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Mar 11, 2022 | 23 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 18, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 11, 2022 | 24 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Preliminary Infringement Contentions for Defendant Lupin Inc. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 1, 2022 | 22 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of 1. Defendants' First Set of Requests to Dana-Farber Cancer Institute, Inc. for the Production of Documents and Things (Nos. 1-73) 2. Defendants' First Set of Requests to Novartis Pharmaceuticals Corp. for the Production of Documents and Things (Nos. 1-73) filed by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
| Feb 25, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (21 in 1:21-cv-01105-LPS, 33 in 1:21-cv-01107-LPS, 22 in 1:21-cv-01106-LPS) STIPULATION TO EXTEND TIME the deadline for the parties to submit (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 11, 2022 filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/25/2022. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(etg) |
| Feb 24, 2022 | 21 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME the deadline for the parties to submit (1) an Order for Discovery of ESI and (2) a Proposed Protective Order to March 11, 2022 - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Feb 16, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (19 in 1:21-cv-01105-LPS, 31 in 1:21-cv-01107-LPS, 20 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Robert W. Trenchard filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/16/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Feb 15, 2022 | 19 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Robert W. Trenchard - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Robert W. Trenchard)(Silver, Daniel) |
| Feb 15, 2022 | 19 | Certification for Robert W. Trenchard (1) |
| Feb 15, 2022 | 20 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Kyanna Sabanoglu as co-counsel.. (Silver, Daniel) |
| Feb 9, 2022 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(Taylor, Daniel) |
| Feb 9, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 2/9/2020. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(dlb) |
| Feb 8, 2022 | 17 | Scheduling Order (17) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 12/16/2022. Status Report due by 9/2/2022. Joint Claim Construction Brief due by 11/9/2022. A Markman Hearing is set for 11/28/2022 at 02:00 PM before Judge Leonard P. Stark. Proposed Pretrial Order due by 8/4/2023. A Final Pretrial Conference is set for 8/11/2023 at 01:00 PM before Judge Leonard P. Stark. A 5-day Bench Trial is set for 8/21/2023 at 08:30 AM before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 2/8/22. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Jan 19, 2022 | 16 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); (2) Plaintiffs' Paragraph 3 Disclosures; and (3) Plaintiffs' Initial Disclosures of Accused Products and Asserted Patents filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 18, 2022 | 15 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Lupin Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Defendant Lupin Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the District of Delaware's Default Standard for Discovery filed by Lupin Inc..(Lennon, James) |
| Jan 6, 2022 | 13 | Proposed Order (19) Docket Text: PROPOSED ORDER Scheduling by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 6, 2022 | 14 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Stipulated Proposed Scheduling Order - re (22 in 1:21-cv-01107-LPS, 13 in 1:21-cv-01105-LPS, 13 in 1:21-cv-01106-LPS) Proposed Order. (Silver, Daniel) |
| Oct 28, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [12] MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Holub, Deepro R. Mukerjee, Joseph M. Janusz, and Lance Soderstrom filed by Lupin Inc. Signed by Judge Leonard P. Stark on 10/28/21. (ntl) |
| Oct 27, 2021 | 12 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Holub, Deepro R. Mukerjee, Joseph M. Janusz, and Lance Soderstrom - filed by Lupin Inc.. (Devlin, Timothy) |
| Sep 17, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Kyanna Sabanoglu, Anne Y. Brody, Ronald A. Lee, Sung Bin Lee for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Sep 17, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jane M. Love for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Sep 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (14 in 1:21-cv-01107-LPS, 11 in 1:21-cv-01105-LPS, 12 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/16/21. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl) |
| Sep 15, 2021 | 11 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee)(Silver, Daniel) |
| Sep 15, 2021 | 11 | Certifications for Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, (5) |
| Sep 10, 2021 | 10 | Answer to Counterclaim (6) Docket Text: ANSWER to [8] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 20, 2021 | 8 | Answer to Complaint (15) Docket Text: ANSWER to [1] Complaint , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Lupin Inc..(Lennon, James) |
| Aug 20, 2021 | 9 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited, Corporate Parent Nanomi B.V. for Lupin Inc. filed by Lupin Inc.. (Lennon, James) |
| Aug 4, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (rjb) |
| Jul 30, 2021 | 6 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Lupin Inc. on 7/30/2021. (mal) |
| Jul 30, 2021 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Lupin Inc. served on 7/30/2021, answer due 8/20/2021. (Joyce, Alexandra) |
| Jul 29, 2021 | 1 | Main Document (8) Docket Text: COMPLAINT filed against Lupin Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3668317.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(mal) |
| Jul 29, 2021 | 1 | Exhibit A (22) |
| Jul 29, 2021 | 1 | Civil Cover Sheet (2) |
| Jul 29, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Jul 29, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than 06/14/2021. Date of Expiration of Patent: 12/2/2030 (8,575,146). Thirty Month Stay Deadline: No Earlier than 12/14/2023 (mal) |
| Jul 29, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,575,146. (mal) |
| Jul 29, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mal) |
| Jul 29, 2021 | 1 | Complaint* (1) |
